A Phase 1/2 interventional study of Aflibercept and Endolaserless Vitrectomy in Proliferative Diabetic Retinopathy, sponsored by Southeast Retina Center, Georgia. Status unknown at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-29.
Sponsored by Southeast Retina Center, Georgia · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days but >7 days prior to vitrectomy and one intraoperative IAI at end of surgery followed by randomization in a 1:1 ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group).
This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days but >7 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery followed by randomization in a 1:1 ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group).
Follow-up visits occur 1 day and 1-2 weeks, and 4 weeks postoperatively and then every 4 weeks from the first postoperative IAI for 52 weeks. One preoperative visit and every postoperative visit (except day one postoperatively) will include ETDRS Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP) measurement, Slit lamp biomicroscopy, Indirect ophthalmoscopy, Heidelberg Spectralis Spectral Domain Optical Coherence Tomography (SD-OCT) (no OCT for preoperative visit) and evaluation for systemic and ocular adverse events. Seven standard field photographs and Optos wide-field fluorescein angiography will be performed at postoperative visits at 4, 16, 28, 40,and 52 weeks. Humphrey visual field (HVF) testing (30-2 and 60-4 test patterns) will be performed at postoperative visits at 4 and 52 weeks. Preoperative B scan echography will be required standard of care(SOC) to assess for macular traction, non-macular traction, retinal detachment and vitreous hemorrhage(VH). Identification of traction macular detachment will exclude the patient from the study.
44 studies on the registry are indexed under Vitreous Hemorrhage; 4 are open to participants now.
This study's planned enrollment of 24 is below the median of 56 across 34 interventional studies indexed under Vitreous Hemorrhage.
Browse Vitreous Hemorrhage studies →Southeast Retina Center, Georgia is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group ("q8 week Group") where 4 additional mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up. Starting at week 20 in the q8week group eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment
Drug: Aflibercept · Procedure: Endolaserless Vitrectomy
Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q16week Group) where 2 additional mandatory postoperative q4weeks IAI will be followed by mandatory q16weeks IAI for 52 weeks follow-up. Starting at week 12 in the q16 group, eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment.
Drug: Aflibercept · Procedure: Endolaserless Vitrectomy
. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
Also known as: Eylea, 2 mg/0.05 mL single use vial for intravitreal injection
Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
• Ocular and systemic safety evaluation for adverse events at any time point through 52 weeks:
Examples include worsened acuity \>30 letters, rhegmatogenous or tractional retinal detachment, endophthalmitis, new or increased vitreous hemorrhage, cataract progression or surgery, need for additional vitrectomy or scleral buckle, development of new DME after OCT documentation of absence of DME, systemic thromboembolic events, deaths and systemic serious adverse events at any time point through week 52.
Time frame: Through 52 weeks from Baseline
Mean change in BCVA letter score
Mean change in BCVA letter score over time through week 52
Time frame: 52 weeks from Baseline
Mean BCVA letter score
Mean BCVA letter score over time through week 52
Time frame: 52 weeks from Baseline
Proportion of eyes with progression of PDR
Proportion of eyes with progression of PDR as defined above at any time point through week 52
Time frame: Through 52 weeks from Baseline
Mean OCT CSF thickness
Mean OCT CSF thickness over time through week 52
Time frame: Through 52 weeks from Baseline
Proportion of eyes with OCT CSF thickness <300um
Proportion of eyes with OCT CSF thickness \<300um at week 52
Time frame: Through 52 weeks from Baseline
Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage
Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage at week 52
Time frame: Through 52 weeks from Baseline
Proportion of eyes with absence of active neovascularization
Proportion of eyes with absence of active neovascularization by Optos widefield fluorescein angiography at week 52
Time frame: Through 52 weeks from Baseline
Proportion of eyes with absence of active neovascularization
Proportion of eyes with absence of active neovascularization by 7 standard field photography at week 52
Time frame: Through 52 weeks from Baseline
Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage
Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage from baseline angiograms at week 52
Time frame: Through 52 weeks from Baseline
Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic neovascularization
Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic neovascularization from baseline angiograms at week 52
Time frame: Through 52 weeks from Baseline
Proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance
Proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance from baseline photographs at week 52
Time frame: Through 52 weeks from Baseline
Mean cumulative score and change for the combined 30-2 and 60-4 HVF test
Mean cumulative score and change for the combined 30-2 and 60-4 HVF test from week 4 to week 52.
Time frame: Through 52 weeks from Baseline
Proportion of eyes requiring additional IAI other than mandatory injections
Proportion of eyes requiring additional IAI other than mandatory injections through week 52
Time frame: Through 52 weeks from Baseline
Proportion of eye with progression of PDR requiring rescue PRP standard of care
Proportion of eye with progression of PDR requiring rescue PRP standard of care at any time point through 52 weeks
Time frame: Through 52 weeks from Baseline
Proportion of eyes requiring PRP or retinopexy
Proportion of eyes requiring PRP or retinopexy through week 52
Time frame: Through 52 weeks from Baseline
Proportion of eyes requiring additional vitrectomy
Proportion of eyes requiring additional vitrectomy through week 52
Time frame: Through 52 weeks from Baseline
Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy
Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy
Time frame: Through 52 weeks from Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Jun 2016, a primary completion of Jun 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept
Southeast Retina Center, Georgia